Prospective Comparison of Dual Wavelength Long-Pulsed 755-nm Alexandrite/1,064-nm Neodymium:Yttrium-Aluminum-Garnet Laser versus 585-nm Pulsed Dye Laser Treatment for Rosacea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, Hyun-Min | - |
dc.contributor.author | Kim, Jung-In | - |
dc.contributor.author | Kim, Han-Saem | - |
dc.contributor.author | Choi, Young-Jun | - |
dc.contributor.author | Kim, Won-Serk | - |
dc.date.accessioned | 2022-07-15T07:10:22Z | - |
dc.date.available | 2022-07-15T07:10:22Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 1013-9087 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/153955 | - |
dc.description.abstract | Background: Rosacea treatments including oral/topical medications and laser therapy are numerous but unsatisfactory. Objective: To compare the effectiveness of the dual wavelength long-pulsed 755-nm alexandrite/1,064-nm neodymium:yttrium-aluminum-garnet laser (LPAN) with that of 585-nm pulsed dye laser (PDL) for rosacea. Methods: This was a randomized, single-blinded, comparative study. Full face received four consecutive monthly treatments with LPAN or PDL, followed-up for 6 months after the last treatment. Erythema index was measured by spectrophotometer, and digital photographs were evaluated by consultant dermatologists for physician's global assessment. Subjective satisfaction surveys and adverse effects were recorded. Results: Forty-nine subjects with rosacea enrolled and 12 dropped out. There were no significant differences between LPAN and PDL in the mean reduction of the erythema index (p=0.812; 3.6% vs. 2.8%), improvement of physician's global assessment (p=1.000; 88.9% vs. 89.5%), and subject-rated treatment satisfaction (p=0.842; 77.8% vs. 84.2%). PDL showed more adverse effects including vesicles than LPAN (p=0.046; 26.3% vs. 0.0%). No other serious or permanent adverse events were observed in both treatments. Conclusion: Both LPAN and PDL may be effective and safe treatments for rosacea. Copyright | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN DERMATOLOGICAL ASSOC | - |
dc.title | Prospective Comparison of Dual Wavelength Long-Pulsed 755-nm Alexandrite/1,064-nm Neodymium:Yttrium-Aluminum-Garnet Laser versus 585-nm Pulsed Dye Laser Treatment for Rosacea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seo, Hyun-Min | - |
dc.identifier.doi | 10.5021/ad.2016.28.5.607 | - |
dc.identifier.scopusid | 2-s2.0-84991451801 | - |
dc.identifier.wosid | 000385786200012 | - |
dc.identifier.bibliographicCitation | ANNALS OF DERMATOLOGY, v.28, no.5, pp.607 - 614 | - |
dc.relation.isPartOf | ANNALS OF DERMATOLOGY | - |
dc.citation.title | ANNALS OF DERMATOLOGY | - |
dc.citation.volume | 28 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 607 | - |
dc.citation.endPage | 614 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.identifier.kciid | ART002152006 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordPlus | TELANGIECTASIA | - |
dc.subject.keywordAuthor | Alexandrite | - |
dc.subject.keywordAuthor | Lasers | - |
dc.subject.keywordAuthor | Neodymium | - |
dc.subject.keywordAuthor | Rosacea | - |
dc.identifier.url | https://anndermatol.org/DOIx.php?id=10.5021/ad.2016.28.5.607 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.